Precision Medicine for Health Plans

Precision Medicine for Health Plans:

Managing coverage and reimbursement amidst the rapid evolution of genetic testing and targeted therapies

The pace of advancement in genetics and precision medicine is staggering. Today, there are more than 75,000 genetic testing products on the market, and more than ⅓ of therapies in the development pipeline are for molecularly-defined conditions. In this webinar, experts in genetic testing, drug spend, and claims payment automation will provide practical insight on the present and future of precision medicine and how leading health plans are managing the space.

Participants on the webinar will learn:

● Which areas of genetic testing are driving growth, spend, and complexity, and where the near-term opportunities are for more effective management;
● What is the state of the market for targeted therapies relative to all pharmaceuticals, and what should plans be preparing for;
● How is genetic-informed medicine changing the claims payment process and how are leading plans adapting.

Presented by:

Todd Cooperman, PharmD, MBA, RPh
Senior Vice President, Clinical Insight and Analytics
RJ Health

Gillian Hooker, PhD, ScM, LCGC
VP, Clinical Development
Concert Genetics

Jared Lorinsky
Chief Strategy Officer
Burgess

Cliff Goodman, PhD (Moderator)
Senior Vice President and Director, Center for Comparative Effectiveness Research
The Lewin Group

 

Register Below Now: